Wei-jing Zhang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: February 10, 2026
Real-World Efficacy of Nab-Paclitaxel Plus Capecitabine and a PD-1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer.
Journal: Cancer medicine
Published: October 13, 2025
Radiation-induced rhinosinusitis in patients with nasopharyngeal carcinoma.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: November 23, 2024
Beyond the tumor region: Peritumoral radiomics enhances prognostic accuracy in locally advanced rectal cancer.
Journal: World journal of gastroenterology
Published: July 12, 2024
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.
Journal: Cell reports. Medicine
Published: July 23, 2023
Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.
Journal: Cell reports. Medicine
Published: March 17, 2023
Assessment of Prophylactic Internal Carotid Artery Management in Postradiation Nasopharyngeal Necrosis Patients.
Journal: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
Published: March 06, 2023
Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study.
Journal: EClinicalMedicine
Published: March 06, 2023
Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 03, 2023
Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
Journal: Med (New York, N.Y.)
Published: March 08, 2022
Dual-region radiomics signature: Integrating primary tumor and lymph node computed tomography features improves survival prediction in esophageal squamous cell cancer.
Journal: Computer methods and programs in biomedicine
Published: April 04, 2021
Correction to: Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups.
Journal: European radiology
Published: April 28, 2019
Last Updated: 09/26/2026